Balaji K. Tamarappoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Balaji K. Tamarappoo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Bashaer Gheyath
Department of Internal Medicine, Cardiovascular Division Healthpoint Hospital Abu Dhabi UAE
1 shared publication - Carolyn Larsen
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA
1 shared publication - Chadi Ayoub
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA
1 shared publication Daniel S. Berman
Cedars Sinai Medical Center, Los Angeles, CA
1 shared publicationFanrong Mu
Siemens Molecular Imaging
1 shared publicationGang Chen
Siemens Molecular Imaging
1 shared publication
Latest Publications
- Open Access
- 26 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3714
Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging
The long-term survivorship of patients diagnosed with cancer has improved due to accelerated detection and rapidly evolving cancer treatment strategies. As such, the evaluation and management of cancer therapy related complications has become increasingly important, including cardiovascular complications. These have been captured under the umbrella term “cardiotoxicity” and include left ventricular dysfunction and heart failure, acute coronary syndromes, valvular abnormalities, pericardial disease, arrhythmia, myocarditis, and vascular complications. These complications add to the burden of cardiovascular disease (CVD) or are risk factors patients with cancer treatment are presenting with. Of note, both pre- and newly developing CVD is of prognostic significance, not only from a cardiovascular perspective but also overall, potentially impacting the level of cancer therapy that is possible. Currently, there are varying recommendations and practices regarding CVD risk assessment and mitigating strategies throughout the cancer continuum. This article provides an overview on this topic, in particular, the role of cardiac imaging in the care of the patient with cancer. Furthermore, it summarizes the current evidence on the spectrum, prevention, and management of chemotherapy-related adverse cardiac effects.
- 26 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3714
Open AccessChemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging
The long-term survivorship of patients diagnosed with cancer has improved due to accelerated detection and rapidly evolving cancer treatment strategies. As such, the evaluation and management of cancer therapy related complications has become increasingly important, including cardiovascular complications. These have been captured under the umbrella term “cardiotoxicity” and include left ventricular dysfunction and heart failure, acute coronary syndromes, valvular abnormalities, pericardial disease, arrhythmia, myocarditis, and vascular complications. These complications add to the burden of cardiovascular disease (CVD) or are risk factors patients with cancer treatment are presenting with. Of note, both pre- and newly developing CVD is of prognostic significance, not only from a cardiovascular perspective but also overall, potentially impacting the level of cancer therapy that is possible. Currently, there are varying recommendations and practices regarding CVD risk assessment and mitigating strategies throughout the cancer continuum. This article provides an overview on this topic, in particular, the role of cardiac imaging in the care of the patient with cancer. Furthermore, it summarizes the current evidence on the spectrum, prevention, and management of chemotherapy-related adverse cardiac effects.
- Open Access
- 14 March 2014
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 21 (3) , 553-562
Atherosclerotic plaque uptake of a novel integrin tracer 18F-Flotegatide in a mouse model of atherosclerosis
- 14 March 2014
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 21 (3) , 553-562
Open AccessAtherosclerotic plaque uptake of a novel integrin tracer 18F-Flotegatide in a mouse model of atherosclerosis